LSE · PRM.L
Proteome Sciences plc
£0.01+£0.00 (+4.29%)
Proteome Sciences plc’s quoted price sits in the lower half of its reported 52-week range, 66.82% below the high.
Loading market information…
LSE · TRX.L · GBp
Stock price, earnings
Quote as of Oct 22, 2025, 04:30 PM UTC. Cached market data; not a live quote.
One-year closing-price history · GBp. Historical prices are not a forecast.
Tissue Regenix Group plc’s quoted price sits in the lower half of its reported 52-week range, 89.02% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Tissue Regenix Group plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Tissue Regenix Group plc, established in 2006 and headquartered in Garforth, United Kingdom, is a medical technology enterprise dedicated to advancing the fields of tissue engineering and regenerative medicine. Operating across the United States and international markets, the company develops and commercializes sophisticated platform technologies. Its operations are organized into BioSurgery, Orthopaedics & Dental, and GBM-V & Cardiac divisions. Tissue Regenix's flagship dCELL technology involves a soft tissue decellularization process, which meticulously removes DNA and cellular material from animal and human tissues to facilitate the repair of diseased or injured body parts. Complementing this is BioRinse technology, a natural bone filler designed to stimulate and promote native bone growth through its osteoinductive properties. The company's diverse product portfolio includes DermaPure, a decellularized dermal allograft used for strengthening, repairing, and replacing compromised skin tissue, and SurgiPure XD, a decellularized porcine dermal matrix for mending hernias and body wall defects. For orthopedic applications, Tissue Regenix offers OrthoPure XT, a regenerative scaffold that allows damaged tissue to repopulate with the patient's own cells, alongside various osteoinductive bone matrices such as ConCelltrate 100 and MatrixCellect 100 DBM. Other notable products include Matrix IQ Dermis, a human-derived dermal graft engineered for revascularization and tissue repair, and Matrix OI FlexIt, a flexible demineralized cortical allograft bone sheet. The company also offers DentalFix, a mineralized particulate allograft designed to leverage the osteoconductive properties of natural bone. Its extensive product line further encompasses CardioPure solutions, Matrix OI 100 DBM for non-structural bone-grafting, Matrix OI Strips and Blocks as stem cell containment scaffolds, AmnioWorks for applications in ophthalmology and wound covering, and a variety of specialized sports medicine products.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:36 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2020 |
|---|
| Apr 28, 2021 |
| -£0.07 |
| £4.95M-68.99% vs estimate |
Latest available per-share figures in GBP. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
£0.01+£0.00 (+4.29%)
Proteome Sciences plc’s quoted price sits in the lower half of its reported 52-week range, 66.82% below the high.
£0.01£0.00 (0.0%)
Cizzle Biotechnology Holdings Plc’s quoted price sits in the lower half of its reported 52-week range, 70.51% below the high.
£0.09-£0.00 (-2.78%)
MyHealthChecked PLC’s quoted price sits in the lower half of its reported 52-week range, 58.33% below the high.
£0.00£0.00 (0.0%)
N4 Pharma Plc’s quoted price sits in the lower half of its reported 52-week range, 52.5% below the high.
£0.00£0.00 (0.0%)
Theracryf Plc’s quoted price sits in the lower half of its reported 52-week range, 34.7% below the high.
£0.00£0.00 (0.0%)
Surgical Innovations Group plc’s quoted price sits in the lower half of its reported 52-week range, 33.33% below the high.
£0.09£0.00 (0.0%)
CRISM Therapeutics Corporation’s quoted price sits in the lower half of its reported 52-week range, 52.7% below the high.
£0.00-£0.00 (-4.09%)
Oxford BioDynamics Plc’s quoted price sits in the lower half of its reported 52-week range, 68.97% below the high.
